SHPT drug Rayaldee now available in Switzerland

1 March 2022

Swiss company Vifor Pharma (SIX: VIFN) today announced the Swiss launch of Rayaldee (extended-release calcifediol), the first and only oral therapy approved in Europe for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and low vitamin D levels (25-hydroxyvitamin D serum levels <30 ng/ml).

Rayaldee was developed OPKO Health (NYSE: OPK) and out-licensed to Vifor in 2016 for territories including Europe. The drug gained US marketing approval in June 20216.

“We are very excited to introduce Rayaldee as a new treatment option for CKD patients in Switzerland living with SHPT”, said Jörg Storre, general manager of Vifor Pharma Switzerland, adding: “The launch in Switzerland demonstrates our commitment to providing innovative medicines to support patients and healthcare providers. We are confident that Rayaldee can become the new standard of care supporting better outcomes for patients and reducing the challenging complications brought on by the disease.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK